HIPK2 knock-down compromises tumor cell efficiency to repair damaged DNA

Biochemical and Biophysical Research Communications

Volumn 361, Issue 1, 2007, Pages 249-255

  Nardinocchi, Lavinia ^a   Puca, Rosa ^a   Sacchi, Ada ^a   D'Orazi, Gabriella ^a,b  

^a REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^b UNIVERSITY OF CHIETI   (Italy)

Author keywords

DNA repair; Host reactivation; p53; p53R2; RNA interference; Tumor progression

Indexed keywords

HOMEODOMAIN INTERACTING PROTEIN KINASE 2; PROTEIN P53; RNA;

ARTICLE; CONTROLLED STUDY; DNA DAMAGE; DNA REPAIR; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; TRANSCRIPTION INITIATION; TUMOR CELL; TUMOR GROWTH; TUMOR SUPPRESSOR GENE;

CARRIER PROTEINS; CELL CYCLE PROTEINS; CELL LINE, TUMOR; DNA DAMAGE; DNA REPAIR; HUMANS; NEOPLASMS; PROTEIN-SERINE-THREONINE KINASES; RIBONUCLEOTIDE REDUCTASES; RNA INTERFERENCE; TRANSCRIPTION, GENETIC; TUMOR SUPPRESSOR PROTEIN P53;

EID: 34547108122     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2007.07.031     Document Type: Article

References (29)

1. Kim Y.H., Choi C.Y., Lee S., Conti M.A., and Kim Y. Homeodomain-interacting protein kinases, a novel family of co-repressors for homeodomain transcription factors. J. Biol. Chem. 273 (1998) 875-879
2. Calzado M.A., Renner F., Roscic A., and Schmitz M.L. HIPK2: a versatile switchboard regulating the transcription machinery and cell death. Cell Cycle 6 (2007) 139-143
3. D'Orazi G., Cecchinelli B., Bruno T., Manni I., Higashimoto Y., Saito S., Gostissa M., Coen S., Marchetti A., Del Sal G., Piaggio G., Fanciulli M., Appella E., and Soddu S. Homeodomain-interacting protein kinase-2 phosphorylates p53 at Ser46 and mediates apoptosis. Nature Cell Biol. 4 (2002) 11-19
4. Hofmann T.G., Moller A., Sirma H., Zentgraf H., Taya Y., Droge W., Will H., and Schmitz M.L. Regulation of p53 activity by its interaction with homeodomain-interacting protein kinase-2. Nature Cell Biol. 4 (2002) 1-10
5. Di Stefano V., Rinaldo C., Sacchi A., Soddu S., and D'Orazi G. Homeodomain-interacting protein kinase-2 activity and p53 phosphorylation are critical events for cisplatin-mediated apoptosis. Exp. Cell Res. 293 (2004) 311-320
6. Di Stefano V., Soddu S., Sacchi A., and D'Orazi G. HIPK2 contributes to PCAF-mediated p53 acetylation and selective transactivation of p21Waf1 after non-apoptotic DNA damage. Oncogene 24 (2005) 5431-5442
7. Hollstein M., Hergenhahn M., Yang Q., Bartsch H., Wang Z.Q., and Hainaut P. New approaches to understanding p53 gene tumor mutation spectra. Mutat. Res. 432 (1999) 199-209
8. Vousden K.H., and Prives C. P53 and prognosis: new insights and further complexity. Cell 120 (2005) 7-10
9. Oren M. Decision making by p53: life, death and cancer. Cell Death Diff. 10 (2003) 431-442
10. Risinger M.A., and Groden J. Crosslinks and crosstalks: human cancer syndromes and DNA repair defects. Cancer Cell 6 (2004) 357-372
11. Sengupta S., and Harris C.C. P53: traffic cop at the crossroads of DNA repair and recombination. Nat. Rev. Mol. Cell. Biol. 6 (2005) 44-55
12. Donehower L.A., Harvey M., Slagle B.L., McArthur M.J., Montgomery Jr. C.A., Butel J.S., and Bradley A. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature 356 (1992) 215-221
13. Jacks T., Remington L., Williams B.O., Schmitt E.M., Halachmi S., and Bronson R.T. Tumor spectrum analysis in p53-mutant mice. Curr. Biol. 4 (1994) 1-7
14. Evans S.C., and Lozano G. The Li-Fraumeni syndrome: an inherited susceptibility to cancer. Mol. Med. Today 3 (1997) 390-395
15. Reifenberger G., Liu L., Ichimura K., Schmidt E.E., and Collis V.P. Amplification and overexpression of the MDM2 gene in a subset of human malignant gliomas without p53 mutations. Cancer Res. 53 (1993) 2736-2739
16. Haupt Y., Maya R., Kazaz A., and Oren M. MDM2 promotes the rapid degradation of p53. Nature 387 (1997) 296-299
17. Kubbutat M.H., Jones S.N., and Vousden K.H. Regulation of p53 stability by MDM2. Nature 387 (1997) 299-303
18. Vogt Sionov R., and Haupt Y. The cellular response to p53: the decision between life and death. Oncogene 18 (1999) 6145-6157
19. Tanaka H., Arakawa H., Yamaguchi T., Shiraishi K., Fukuda S., Matsui K., Takei Y., and Nakamura Y. A ribonucleotide reductase gene involved in a p53-dependent cell-cycle checkpoint for DNA damage. Nature 404 (2000) 42-49
20. Siddique M., and Sabapathy K. Trp53-dependent DNA repair is affected by the codon 72 polymorphism. Oncogene 25 (2006) 3489-3500
21. Vogelstein B., Lane D., and Levine A.J. Surfing the p53 network. Nature 408 (2000) 307-310
22. Laptenko O., and Prives C. Transcriptional regulation by p53: one protein, many possibilities. Cell Death Diff. 13 (2006) 951-961
23. Pierantoni G.M., Bulfone A., Pentimalli F., Fedele M., Iuliano R., Santoro M., Chiariotti L., Ballabio A., and Fusco A. The homeodomain-interacting protein 2 gene is expressed late in embryogenesis and preferentially in retina, muscle, and neural tissues. Biochem. Biophys. Res. Comm. 290 (2002) 942-947
24. D'Orazi G., Sciulli M.G., Di Stefano V., Riccioni S., Frattini M., Falcioni R., Bertario L., Sacchi A., and Patrignani P. Homeodomain-interacting protein kinase-2 restrains cytosolic phospholipase A2-dependent prostaglandin E2 generation in human colorectal cancer cells. Clin. Cancer Res. 12 (2006) 735-741
25. Kastan M.B. Wild-type p53: tumors can't stand it. Cell 128 (2007) 837-840
26. Haupt S., and Haupt Y. Manipulation of the tumor suppressor p53 for potentiating cancer therapy. Semin. Cancer Biol. 14 (2004) 244-252
27. Martins C.P., Brown-Swigart L., and Evan G.I. Modeling the therapeutic efficacy of p53 restoration in tumours. Cell 127 (2006) 1323-1334
28. Xue W., Zender L., Miething C., Dickins R.A., Hernando E., Krizhanovsky V., Cordon-Cardo C., and Lowe S.W. Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature 445 (2007) 656-660
29. Ventura A., Kirsch D.G., McLaughlin M.E., Tuveson D.A., Grimm J., Lintault L., Newman J., Reczek E.E., Weissleder R., and Jacks T. Restoration of p53 function leads to tumour regression in vivo. Nature 445 (2007) 661-665